Business
Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting
MONTPELLIER, France, April 25, 2025--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Pr. Natalie Loundon, pediatric ENT Surgeon, Director of the Center for Research in Pediatric Audiology, Necker Enfants Malades Hospital, AP-HP, in Paris, France, will make an oral presentation at the annual meeting of the American Societ
About this update from Sensorion Sas
[{"type":"text","content":"MONTPELLIER, France, April 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Pr. Natalie Loundon, pediatric ENT Surgeon, Director of the Center for Research in Pediatric Audiology, Necker Enfants Malades Hospital, AP-HP, in Paris, France, will make an oral presentation at the annual meeting of the American Society of Pediatric Otolaryngology (ASPO).","length":483,"tagName":"p"},{"type":"text","content":"The Conference is being held in Montreal, Canada, on April 30 - May 3, 2025, and Pr. Loundon’s talk "Principle and Practice of a Gene Therapy for Hearing loss: A Phase 1/2 Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss" will occur on May 1st at 4.20 pm CET (10.20 am ET).","length":322,"tagName":"p"},{"type":"text","content":"Pr. Loundon is the Principal Investigator of Audiogene, Sensorion’s Phase 1/2 clinical trial evaluating SENS-501, a gene therapy treatment for DFNB9, a genetic disorder causing severe to profound hearing loss due to mutations in the OTOF gene. Her presentation will include an overview of the rationale behind gene therapy approaches for inner ear hearing loss disorders and the Company’s Audiogene clinical trial.","length":414,"tagName":"p"},{"type":"text","content":"About the Audiogene TrialAudiogene aims to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. By targeting the first years of life, when brain plasticity is optimal, the chances of these young children with pre-linguistic hearing loss acquiring normal speech and language are maximized. The study comprises two cohorts of two doses followed by an expansion cohort at the selected dose. While safety will be the primary endpoint of the first part of the dose escalation study, auditory brainstem response (ABR) will be the primary efficacy endpoint of the second part of the expansion. Audiogene will also evaluate the clinical safety, performance and ease-of-use of the delivery system ...